Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel <i>SNX8-BRAF</i> Gene Fusion-Reference-Cited by-同舟云学术

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion

Published:2023-07 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Offer Katharine¹^ORCID,McGuire Michael T.²,Song Kunchang³,Goldfischer Michael J.³,Davare Monika A.⁴^ORCID,Corless Christopher L.⁵,Beadling Carol⁶^ORCID,Neff Tanaya⁵,Cox Michael C.⁷,Govinda Raju Sandya⁷,Blackman Samuel C.⁷

Affiliation:

1. Children's Cancer Institute, Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ

2. Department of Radiology, Hackensack Meridian School of Medicine, Hackensack, NJ

3. Department of Pathology, Hackensack Meridian Health, Hackensack, NJ

4. Department of Pediatrics, Oregon Health & Science University, Portland, OR

5. Knight Diagnostics Laboratory, Oregon Health & Science University, Portland, OR

6. School of Medicine, Oregon Health & Science University, Portland, OR

7. Day One Biopharmaceuticals, Brisbane, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00065

Reference13 articles.

1. Mesenchymal neoplasms with NTRK and other kinase gene alterations

2. Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group

3. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

4. FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors

5. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tovorafenib: First Approval;Drugs;2024-07-05

2. A critical review of RAF inhibitors in BRAF-mutated glioma treatment;Pharmacogenomics;2024-05-02

3. How will tovorafenib change our treatment of pediatric low-grade glioma?;Expert Opinion on Emerging Drugs;2024-01-02

4. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial;Nature Medicine;2023-11-17